Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

Shinichi Tamura, President and CEO of Sosei Heptares commented:"The results from the ARGON Phase IIIb study add to the extensive clinical data that Novartis has generated with once-daily IND/GLY/MF.